Helmut F.
- Country
- Germany
- Department
- Internal Oncology
Research Overview
- Phase III Randomized, Double-Blind Trial of Atezolizumab with Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients
- Evaluation of Ribociclib Combined with Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Phase III Randomized Trial
- Evaluation of Adjuvant Therapy with Capecitabine in Stage II Colon and Rectal Cancer Patients with ctDNA Positivity Post-Resection
Data & Insights
Has run more than one trial at 172 of 491 partner sites.
Specializations
Breast Cancer Research
Specializing in both hormone receptor-positive breast cancer and triple-negative breast cancer treatments, with particular focus on innovative therapeutic approaches.
- Early-stage breast cancer interventions
- Endocrine therapy combinations
- Neoadjuvant chemotherapy applications
Investigates the integration of targeted therapies with conventional treatment modalities.
Gastrointestinal Oncology
Focused on advancing treatment strategies for early-stage colorectal cancer, with emphasis on personalized therapeutic approaches.
- Stage II colon cancer management
- Circulating tumor DNA analysis
- Adjuvant therapy optimization
Explores innovative diagnostic methods to guide treatment decisions in gastrointestinal cancers.
Lymphoma Studies
Specializes in the treatment of advanced Hodgkin lymphoma, focusing on developing improved therapeutic regimens.
- Novel treatment combinations
- Toxicity reduction strategies
- PET-guided radiotherapy
Evaluates innovative approaches to enhance treatment efficacy while minimizing adverse effects.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.